Anti-angiogenesis therapy in cancer: current challenges and future perspectives.
about
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsSubverting Subversion: A Review on the Breast Cancer Microenvironment and Therapeutic OpportunitiesAnti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distributionNext-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityMouse models for studying angiogenesis and lymphangiogenesis in cancerPredictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft modelsSmall molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathwaysUnraveling the Anticancer Effect of Curcumin and ResveratrolApplication of acoustic droplet vaporization in ultrasound therapy.Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group StudyEvaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma.Glutaredoxin regulates vascular development by reversible glutathionylation of sirtuin 1.Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.Vasostatin inhibits VEGF-induced endothelial cell proliferation, tube formation and induces cell apoptosis under oxygen deprivation.In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies.Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysisBlood vessel repair and regeneration in the ischaemic heartMigration and vascular lumen formation of endothelial cells in cancer cell spheroids of various sizes.Effect of Avastin on the number and structure of tumor blood vessels of nude mice with A549 lung adenocarcinoma.(99m)Tc-3P-RGD2 micro-single-photon emission computed tomography/computed tomography provides a rational basis for integrin αvβ3-targeted therapy.Folding and function in α/β-peptides: targets and therapeutic applications.Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials.VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma.Cross-talk between endothelial and tumor cells via basic fibroblast growth factor and vascular endothelial growth factor signaling promotes lung cancer growth and angiogenesis.Tryptanthrin inhibits angiogenesis by targeting the VEGFR2-mediated ERK1/2 signalling pathway.Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors.Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer.Expression of vascular endothelial growth factor and basic fibroblast growth factor in extramammary Paget diseaseProduction of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF.Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis.Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-studyTumor angiogenesis phenotyping by nanoparticle-facilitated magnetic resonance and near-infrared fluorescence molecular imaging.Tube-like structures with co-expression of D2-40 and CD34: newly formed vasculatures?Hypoxia and TGF-β1 lead to endostatin resistance by cooperatively increasing cancer stem cells in A549 transplantation tumorsNCOA1 promotes angiogenesis in breast tumors by simultaneously enhancing both HIF1α- and AP-1-mediated VEGFa transcription.Requirement of novel amino acid fragments of orphan nuclear receptor TR3/Nur77 for its functions in angiogenesisIdentification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells.The prognosis was poorer in colorectal cancers that expressed both VEGF and PROK1 (No correlation coefficient between VEGF and PROK1).Targeting prion-like protein doppel selectively suppresses tumor angiogenesis.
P2860
Q26773795-FE7D3866-FC44-4BCA-AFCC-7417D5C1D9B3Q26784839-75EA553B-0C15-4655-AC2D-F5DCEF72E0DDQ26796955-893C7AD0-22D0-4E91-97D2-331F59BE489DQ26992272-053A95D4-B4DE-46AB-92EC-3859217FC5FAQ27003898-94E58F27-3377-4970-A23A-F87B7D2312D9Q27302122-F4C5A6A0-930A-4CBB-8AB7-91706525268DQ27317155-550468EF-96AE-43DF-B581-06F2963D11E9Q28073155-729DEDC0-01AE-408F-ADEB-A29A2E13D2ECQ30398863-1F9F35CB-D21B-4D65-B1FA-3EE69852EDF4Q30411910-4A22CD01-1D00-469C-8D2C-2FC735A39E05Q30436716-3930EC26-4A96-422E-90A6-24B1AB1CD619Q30559574-90825EB6-651A-4C96-A3A7-F8C4ABA985F9Q31132489-4352048E-128F-4B7E-BF5D-7DB72EDF2FA8Q33580573-96EC92F5-B4F3-4760-A512-CD32FA2B6709Q33819576-3E433F99-D618-403B-9C33-C20B7E77B355Q33926377-77E39138-703D-4598-8ECC-7F23123DC406Q34304413-45C5A0F7-7E6D-461A-B919-754475F30827Q34305816-B2355E2B-6F9A-43CA-A6A9-02286A9AA18EQ34443953-A0D5B709-1CB4-4589-B0CC-4EBDF56FB2A8Q34471067-B91393DC-8F3D-43C1-BA35-191ABDD16689Q34483276-7307EC89-D7C7-4E77-9380-CE1FD179A245Q34531474-E1382C9F-937A-48EF-9C9B-583443C6ABA3Q34693856-FD687987-69C6-407C-BADC-DF69B97377B7Q35042233-E1A410DE-867E-473A-B087-0B4A6935BCCBQ35072701-BE9EA620-EBCB-44A8-96C2-4D4C3F1BA3BBQ35077659-1A22C031-5FA7-4B12-B898-6686E809E3B4Q35124738-291C94D9-45F9-400E-88BC-3748432039ABQ35407573-479A41CA-DC41-4CC7-B94B-87FA5B751D3AQ35632284-44DA2E7E-EFEB-404B-836A-87A04A41DBABQ35657061-8E4ADDC4-BD5F-4D09-B2EE-B00ED134B717Q35782469-B4DCA87D-5BA2-490A-A44C-8054F3AB86E2Q36207673-37E14232-D2CF-4D33-A452-37150DDC367EQ36343788-AAC8FCC4-1333-45B4-B9A3-2EF1D059E5A1Q36378151-6436DFC4-B112-465B-BE3E-DA396C68781DQ36401950-82305F2B-349F-40C7-ACEE-C924717E52D9Q36414332-1A18C57A-1158-4755-A5DC-702E72F0FBF0Q36414440-6D0E77B7-7070-48C0-A318-35ACEB3BCA13Q36454459-57CA2A9A-B194-4E3A-979D-E27AABA5E6FAQ36557136-89BC1518-5971-4D46-BF9C-EA23F59F51F2Q36737935-FEDAA006-DD64-404B-A17A-858C5013B7EB
P2860
Anti-angiogenesis therapy in cancer: current challenges and future perspectives.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Anti-angiogenesis therapy in cancer: current challenges and future perspectives.
@en
Anti-angiogenesis therapy in cancer: current challenges and future perspectives.
@nl
type
label
Anti-angiogenesis therapy in cancer: current challenges and future perspectives.
@en
Anti-angiogenesis therapy in cancer: current challenges and future perspectives.
@nl
prefLabel
Anti-angiogenesis therapy in cancer: current challenges and future perspectives.
@en
Anti-angiogenesis therapy in cancer: current challenges and future perspectives.
@nl
P1433
P1476
Anti-angiogenesis therapy in cancer: current challenges and future perspectives.
@en
P2093
Farbod Shojaei
P304
P356
10.1016/J.CANLET.2012.03.008
P407
P577
2012-03-13T00:00:00Z